Trial Outcomes & Findings for Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery (NCT NCT03036384)
NCT ID: NCT03036384
Last Updated: 2020-05-06
Results Overview
The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision
COMPLETED
PHASE2
40 participants
during surgery (average 1 hour)
2020-05-06
Participant Flow
All participants were recruited at CHU Saint-Pierre.
Possible doses of HB prilocaine range from 30 to 55mg, but actual administrated doses will be defined by CRM
Participant milestones
| Measure |
Cohort 1
45mg HB prilocaine initial dose; 4 patients
|
Cohort 2
40mg HB prilocaine following CRM results; 4 patients
|
Cohort 3
40mg HB prilocaine following CRM results; 4 patients
|
Cohort 4
35mg HB prilocaine following CRM results; 4 patients
|
Cohort 5
50mg HB prilocaine following CRM results, 4 patients
|
Cohort 6
45mg HB prilocaine following CRM results, 4 patients
|
Cohort 7
45mg HB prilocaine following CRM results, 4 patients
|
Cohort 8
45mg HB prilocaine following CRM results, 4 patients
|
Cohort 9
40mg HB prilocaine following CRM results, 4 patients
|
Cohort 10
45mg HB prilocaine following CRM results, 4 patients
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
Overall Study
COMPLETED
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery
Baseline characteristics by cohort
| Measure |
35mg HB Prilocaine
n=4 Participants
|
40mg HB Prilocaine
n=12 Participants
|
45mg HB Prilocaine
n=20 Participants
|
50mg HB Prilocaine
n=4 Participants
|
Total
n=40 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
29 years
STANDARD_DEVIATION 8.76 • n=99 Participants
|
35.08 years
STANDARD_DEVIATION 5.11 • n=107 Participants
|
32.85 years
STANDARD_DEVIATION 4.93 • n=206 Participants
|
29.85 years
STANDARD_DEVIATION 5.94 • n=7 Participants
|
32.75 years
STANDARD_DEVIATION 5.69 • n=31 Participants
|
|
Sex/Gender, Customized
Female
|
4 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
40 Participants
n=31 Participants
|
|
Sex/Gender, Customized
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
|
Length
|
159.5 cm
STANDARD_DEVIATION 4.93 • n=99 Participants
|
164.42 cm
STANDARD_DEVIATION 4.45 • n=107 Participants
|
162.8 cm
STANDARD_DEVIATION 6.26 • n=206 Participants
|
157 cm
STANDARD_DEVIATION 6.16 • n=7 Participants
|
162.38 cm
STANDARD_DEVIATION 5.89 • n=31 Participants
|
|
Weight
|
73 kg
STANDARD_DEVIATION 16.02 • n=99 Participants
|
82.17 kg
STANDARD_DEVIATION 11.93 • n=107 Participants
|
79.78 kg
STANDARD_DEVIATION 11.6 • n=206 Participants
|
84.68 kg
STANDARD_DEVIATION 2.88 • n=7 Participants
|
80.31 kg
STANDARD_DEVIATION 11.62 • n=31 Participants
|
|
Gravity
|
3 number of pregnancies
STANDARD_DEVIATION 1.41 • n=99 Participants
|
2.17 number of pregnancies
STANDARD_DEVIATION 1.03 • n=107 Participants
|
3.1 number of pregnancies
STANDARD_DEVIATION 1.98 • n=206 Participants
|
2 number of pregnancies
STANDARD_DEVIATION 0.96 • n=7 Participants
|
2.70 number of pregnancies
STANDARD_DEVIATION 1.47 • n=31 Participants
|
|
Parity
|
1.25 number of deliveries
STANDARD_DEVIATION 0.5 • n=99 Participants
|
0.67 number of deliveries
STANDARD_DEVIATION 0.49 • n=107 Participants
|
1.3 number of deliveries
STANDARD_DEVIATION 1.98 • n=206 Participants
|
0.75 number of deliveries
STANDARD_DEVIATION 0.96 • n=7 Participants
|
1.05 number of deliveries
STANDARD_DEVIATION 1.47 • n=31 Participants
|
|
Previous Caesarean Section (CS)
no previous caeserean
|
2 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
22 Participants
n=31 Participants
|
|
Previous Caesarean Section (CS)
1 previous caeserean
|
2 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
18 Participants
n=31 Participants
|
|
Term
|
38.5 weeks
STANDARD_DEVIATION 0.58 • n=99 Participants
|
38.42 weeks
STANDARD_DEVIATION 1.08 • n=107 Participants
|
38.40 weeks
STANDARD_DEVIATION 0.94 • n=206 Participants
|
38.75 weeks
STANDARD_DEVIATION 1.26 • n=7 Participants
|
38.45 weeks
STANDARD_DEVIATION 0.96 • n=31 Participants
|
PRIMARY outcome
Timeframe: during surgery (average 1 hour)The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision
Outcome measures
| Measure |
Cohort 1
n=4 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
n=4 Participants
40mg
|
Cohort 4
n=4 Participants
35mg
|
Cohort 5
n=4 Participants
50mg
|
Cohort 6
n=4 Participants
45mg
|
Cohort 7
n=4 Participants
45mg
|
Cohort 8
n=4 Participants
45mg
|
Cohort 9
n=4 Participants
40mg
|
Cohort 10
n=4 Participants
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Success of Anesthesia
Success
|
4 Participants
|
4 Participants
|
4 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
|
Success of Anesthesia
Failure
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Until complete release of sensory block (T12-S1) (average 4 hours)Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1).
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Sensitive Block Duration
|
2.31 hours
Standard Deviation 0.48
|
3.25 hours
Standard Deviation 0.50
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Until complete release of sensory block (T12-S1) (average 4 hours)Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1). For this study, dermatome levels are depicted on a scale ranging from 1 to 18. (1 to 12 = T1-T12 thoracic levels; 13 to 17 = L1-L5 lumbar levels; 18 = S1 sacral level)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Sensitive Block at End of Surgery
|
3.88 Dermatome level
Standard Deviation 1.59
|
3.00 Dermatome level
Standard Deviation 0.82
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Until complete release of motor block (Bromage scale = 1; average 4 hours)Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 minutes after spinal anaesthesia (T0) and until the end of surgery. Duration was defined from the time of the spinal injection until Bromage scale = 1.
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Motor Block Duration
|
2.75 hours
Standard Deviation 0.45
|
3.50 hours
Standard Deviation 0.58
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Until complete release of motor block (average 4 hours)Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 min after spinal anaesthesia (T0) and until the end of surgery.
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Bromage Motor Block Level at End of Surgery
|
3.56 score on a scale
Standard Deviation 0.51
|
4.00 score on a scale
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 10 minutes after baby extractionPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Newborn Apgar score assessed at 1, 5, 10 minutes after baby extraction. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from 0 to 2, then summing up the five values thus obtained. The overall resulting score ranges from 0 to 10 ( 0-3 : severely depressed, 4-6 : Moderately depressed and 7-10 : Excellent condition). The five criteria are summarized using words chosen to form an abbreviation (Appearance, Pulse, Grimace, Activity, Respiration).
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Newborn Apgar Score
Apgar at 1 minute
|
8.47 score on a scale
Standard Deviation 1.84
|
9.00 score on a scale
Standard Deviation 0.82
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Newborn Apgar Score
Apgar at 5 minutes
|
9.63 score on a scale
Standard Deviation 0.96
|
9.75 score on a scale
Standard Deviation 0.50
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Newborn Apgar Score
Apgar at 10 minutes
|
9.84 score on a scale
Standard Deviation 0.50
|
10 score on a scale
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: average 1 hourPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Newborn Methemoglobinemia (MetHb) will be assessed at delivery by cordal blood sample, as a routine control, and expressed as a percentage of total hemoglobinemia.
Outcome measures
| Measure |
Cohort 1
n=10 Participants
45mg
|
Cohort 2
n=1 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Newborn Methemoglobinemia (MetHb)
|
1.59 percentage of MetHb
Standard Deviation 0.53
|
1.60 percentage of MetHb
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: during surgery (average 1 hour)Population: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Arterial blood pressure will be measured at every 2.5 minute during surgery, then at every 20 minutes in the PACU (Post Anesthesia Care Unit). Vasopressors were given for patients with low blood pressure. A low blood pressure is defined as a blood pressure lower than 20% or more than the basal blood pressure (Systolic blood pressure before spinal anesthesia).
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants Needing Vasopressors
|
15 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 5 DaysPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
TNS are defined as pain and/or dysesthesia occurred after complete release of sensory block at the gluteal level, at the thighs and at the legs. At Day 0, Day 1, Day 3 and Day 5
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Transient Neurologic Symptoms (TNS)
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 24 hours after surgeryPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Nausea or Vomiting
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 24 hours after surgeryPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Pruritus
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 24 hours after surgeryPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
All parturients will be questioned for urinary retention (yes or no)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Urinary Retention
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 24 hours after surgeryPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
All parturients will be questioned for dizziness (yes or no)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dizziness
|
5 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 1 hour after surgeryPopulation: Secondary outcomes are presented only for doses of 45 and 50mg HB prilocaine, which are the nearest of the final ED95
Maternal satisfaction (yes or no) will be assessed 1 hour after surgery in the PACU (Post Anesthesia Care Unit)
Outcome measures
| Measure |
Cohort 1
n=19 Participants
45mg
|
Cohort 2
n=4 Participants
40mg
|
Cohort 3
40mg
|
Cohort 4
35mg
|
Cohort 5
50mg
|
Cohort 6
45mg
|
Cohort 7
45mg
|
Cohort 8
45mg
|
Cohort 9
40mg
|
Cohort 10
45mg
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Satisfied Participants
|
16 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
35mg HB Prilocaine
40mg HB Prilocaine
45mg HB Prilocaine
50mg HB Prilocaine
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Panayota Kapessidou
Centre Hospitalier Universitaire Saint Pierre
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place